|
產品背景
|
Under normal conditions, activation of either of the complement pathways leads to the formation of C3 convertase enzymes which cleave C3 into two fragments C3a,an anaphylatoxin,and C3b. The C3b fragment has many biologic functions1 including promotion of phagocytosis and participation as a structural component in both the C3 and C5 convertase enzymes. These processes are understringent control in vivo. One control mechanism involves a two-site cleavage of C3b by Factor I with the cooperation of Factor H or CR1 as cofactors. When cleaved in this way the biologic functions of C3b are lost. The resulting protein is termed iC3b. This fragment, in turn, has a host of new biologic activities.1
|
|
參考資料
|
1、Tamerius, J.D., Pangburn, M.K., et al. Detection of a neoAntigen on human iC3b and C3d by monoclonal Antibody, J. Immunol. 135:2015, 1985.
2、Tamerius, J.D., Pangburn, M.K., et al. Selective inhibition of functional sites of cell bound C3b by hybridoma derived antibodies, J. Immunol 128:512, 1982.
3、Rogers, J., Cooper, N., et al. Complement Activation by ?-amyloid in Alzheimer disease. PNAS 89:10016-10020, 1992.
|
